publication date: Oct. 30, 2015

Helzlsouer Named NCI DCCPS Chief Medical Officer 


KATHY HELZLSOUER was named chief medical officer and an associate director in NCI’s Division of Cancer Control and Population Sciences.

Helzlsouer will direct the Epidemiology and Genomics Research Program, which includes the Office of the Associate Director, Clinical and Translational Epidemiology Branch, Environmental Epidemiology Branch, Genomic Epidemiology Branch, Methods and Technologies Branch, and Risk Factor Assessment Branch.

DCCPS Director Robert Croyle said, “Dr. Helzlsouer is a highly accomplished epidemiologist and clinician with a broad vision of cancer epidemiology, prevention, and control. She brings a valuable blend of medical, scientific, and leadership skills, which will be a strong asset for NCI and DCCPS.”

Prior to joining NCI, she was a professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and, since 2004, directed The Prevention & Research Center which she established at Mercy Medical Center in Baltimore. Her research interests are focused in cancer etiology and prevention, cancer survivorship, and clinical and translational research.

She also is an associate editor of the Journal of the National Cancer Institute and a member of NCI’s PDQ Screening and Prevention Editorial Board. Helzlsouer is a recipient of the Martin D. Abeloff Award for Excellence in Public Health and Cancer Control for her service on the Maryland State Council on Cancer Control.


INOVA named Thomas Graves as vice president for cancer services and Jeanny Aragon-Ching as clinical program director of genitourinary cancers at the Dwight … Continue reading 41-40 Helzlsouer Named NCI DCCPS Chief Medical Officer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.